1Mehta, SH, Morgan, JC, Sethi, KD. Drug-induced movement disorders. Neurol Clin 2015; 33: 153–74.
2Meyer, JM. Forgotten but not gone: new developments in the understanding and treatment of tardive dyskinesia. CNS Spectr 2016; 21 (suppl 1): 13–24.
3Peluso, MJ, Lewis, SW, Barnes, TR, Jones, PB. Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs. Br J Psychiatry 2012; 200: 387–92.
4Patterson, TL, Kaplan, RM, Grant, I, Semple, SJ, Moscona, S, Koch, WL, et al. Quality of well-being in late-life psychosis. Psychiatry Res 1996; 63: 169–81.
5Hofer, A, Kemmler, G, Eder, U, Edlinger, M, Hummer, M, Fleischhacker, WW. Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication and side effects. J Clin Psychiatry 2004; 65: 932–9.
6Bebbington, PE, Angermeyer, M, Azorin, JM, Marwaha, S, Marteau, F, Toumi, M. Side effects of antipsychotic medication and health-related quality of life in schizophrenia. Acta Psychiatr Scand Suppl 2009; 438: 22–8.
7Adrianzén, C, Arango-Davila, C, Araujo, DM, Ruiz, I, Walton, RJ, Dossenbach, M, et al. Relative association of treatment-emergent adverse events with quality of life of patients with schizophrenia: post hoc analysis from a 3-year observational study. Hum Psychopharmacol 2010; 25: 439–47.
8Park, IJ, Jung, DC, Hwang, SS, Jung, HY, Yoon, JS, Kim, CE, et al. The longitudinal trends in the relationship between drug-induced extrapyramidal symptoms and personal and social performance in a population of the patients with schizophrenia: a latent growth model. Psychiatry Res 2016; 238: 33–9.
9Browne, S, Roe, M, Lane, A, Gervin, M, Morris, M, Kinsella, A, et al. Quality of life in schizophrenia: relationship to sociodemographic factors, symptomatology and tardive dyskinesia. Acta Psychiatr Scand 1996; 94: 118–24.
10Chong, SA, Remington, G, Mahendran, R, Chua, HC. Awareness of tardive dyskinesia in Asian patients with schizophrenia. J Clin Psychopharmacol 2001; 21: 235–7.
11Emsley, R, Niehaus, DJ, Oosthuizen, PP, Koen, L, Chiliza, B, Fincham, D. Subjective awareness of tardive dyskinesia and insight in schizophrenia. Eur Psychiatry 2011; 26: 293–6.
12Glazer, WM. Review of incidence studies of tardive dyskinesia associated with typical antipsychotics. J Clin Psychiatry 2000; 61 (suppl 4): 15–20.
13Ascher-Svanum, H, Zhu, B, Faries, D, Peng, X, Kinon, BJ, Tohen, M. Tardive dyskinesia and the 3-year course of schizophrenia: results from a large, prospective, naturalistic study. J Clin Psychiatry 2008; 69: 1580–8.
14Correll, CU, Schenk, EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry 2008; 21: 151–6.
15Modestin, J, Wehrli, MV, Stephan, PL, Agarwalla, P. Evolution of neuroleptic-induced extrapyramidal syndromes under long-term neuroleptic treatment. Schizophr Res 2008; 100: 97–107.
16Go, CL, Rosales, RL, Caraos, RJ, Fernandez, HH. The current prevalence and factors associated with tardive dyskinesia among Filipino schizophrenic patients. Parkinsonism Relat Disord 2009; 15: 655–9.
17Bakker, PR, de Groot, IW, van Os, J, van Harten, PN. Long-stay psychiatric patients: a prospective study revealing persistent antipsychotic-induced movement disorder. PLoS ONE 2011; 6: e25588.
18Janno, S, Holi, M, Tuisku, K, Wahlbeck, K. Prevalence of neuroleptic-induced movement disorders in chronic schizophrenia inpatients. Am J Psychiatry 2004; 161: 160–3.
19Mentzel, TQ, Lieverse, R, Bloemen, O, Viechtbauer, W, van Harten, PN; Genetic Risk and Outcome of Psychosis (GROUP) Investigators. High incidence and prevalence of drug-related movement disorders in young patients with psychotic disorders. J Clin Psychopharmacol 2017; 37: 231–8.
20Kim, JH, Byun, HJ. Prevalence and characteristics of subjective akathisia, objective akathisia, and mixed akathisia in chronic schizophrenic subjects. Clin Neuropharmacol 2003; 26: 312–6.
21Royal College of Psychiatrists. Report of the National Audit of Schizophrenia (NAS) 2012. Healthcare Quality Improvement Partnership, 2012.
22National Institute of Mental Health. Abnormal involuntary movement scale. In ECDU Assessment Manual (ed Guy, W): 534. Department of Health, Education and Welfare, 1976.
23Simpson, GM, Angus, JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970; 212: 11–9.
24Barnes, TRE. A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154: 672–6.
25Chouinard, G, Margolese, HC. Manual for the extrapyramidal symptom rating scale (ESRS). Schizophr Res 2005; 76: 247–65.
26Pietracupa, S, Bruno, E, Cavanna, AE, Falla, M, Zappia, M, Colosimo, C. Scales for hyperkinetic disorders: a systematic review. J Neurol Sci 2015; 358: 9–21.
27Molloy, L, Lakeman, R, Walker, K. More satisfying than factory work: an analysis of mental health nursing using a print media archive. Issues Ment Health Nurs 2016; 37: 550–5.
28Dempsey, A, Ribak, J. The future of the psychiatric mental health clinical nurse specialist: evolution or extinction. Psychiatr Clin North Am 2015; 38: 121–30.
29Cusack, E, Killoury, F, Nugent, LE. The professional psychiatric/mental health nurse: skills, competencies and supports required to adopt recovery-orientated policy in practice. J Psychiatr Ment Health Nurs 2017; 24: 93–104.
30American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorder (5th edn) (DSM-5). APA, 2013.
31Akaike, H. A new look at the statistical model identification. IEEE Trans Automat Control 1974; 19: 716–23.
32Bland, JM, Altman, DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 327: 307–10.
33Curtis, LA, Burns, A. Unit Costs of Health and Social Care 2017. Personal Social Services Research Unit, University of Kent, 2017.